for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Recipharm AB (publ)

RECIb.ST

Latest Trade

144.90SEK

Change

0.50(+0.35%)

Volume

85,769

Today's Range

144.00

 - 

147.00

52 Week Range

107.60

 - 

158.30

As of on the Stockholm Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
144.40
Open
145.00
Volume
85,769
3M AVG Volume
3.58
Today's High
147.00
Today's Low
144.00
52 Week High
158.30
52 Week Low
107.60
Shares Out (MIL)
68.15
Market Cap (MIL)
7,614.92
Forward P/E
28.05
Dividend (Yield %)
0.86

Next Event

Q4 2019 Recipharm AB (publ) Earnings Release

Latest Developments

More

Recipharm Gets Clearance From German Competition Authorities For Offer To Acquire Consort Medical

Recipharm Partners With Aptahem For Formulation Of Apta-1 Drug Candidate

Recipharm: Larger Institutional Shareholders Support Co's Cash Offer For Consort Medical And Subsequent Rights Issue

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Recipharm AB (publ)

Recipharm publ AB is a Sweden-based pharmaceutical company, operating as a Contract Development and Manufacturing Organization (CDMO). It is divided in two business areas: Manufacturing Services, supplying a range of pharmaceutical products in different dosage forms, such as solid dose, semi solids, beta-lactams, hormones, dry powder metered dose inhalers, oral liquids and granulates, among others; and Development and Technology, offering clinical supply, product development, formulation, analytical development, stability studies, packaging development and raw material selection, as well as regulatory advice. It is also engaged in the development of own product portfolio. The Company targets two customer segments: large pharmaceutical companies, outsourcing part of their production; and small and medium-sized enterprises, outsourcing manufacturing and development services. Recipharm publ AB operates as a parent entity of the Recipharm Group, comprising approximately 15 subsidiaries.

Industry

Biotechnology & Drugs

Contact Info

Box 603, Drottninggatan 29

+46.8.6025200

https://www.recipharm.com/

Executive Leadership

Lars Backsell

Chairman of the Board

Thomas Eldered

Chief Executive Officer, Director

Tobias Hagglov

Chief Financial Officer

Jean-Francois Hilaire

Executive Vice President, Strategy and Global Integration

Mark Quick

Executive Vice President, Corporate Development

Key Stats

2.00 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, SEK)

2016

4.7K

2017

5.3K

2018

6.4K

2019(E)

7.4K
EPS (SEK)

2016

3.320

2017

1.100

2018

2.730

2019(E)

5.165
Price To Earnings (TTM)
49.07
Price To Sales (TTM)
1.06
Price To Book (MRQ)
1.69
Price To Cash Flow (TTM)
8.29
Total Debt To Equity (MRQ)
82.46
LT Debt To Equity (MRQ)
80.42
Return on Investment (TTM)
1.85
Return on Equity (TTM)
1.65

Latest News

Latest News

BRIEF-Recipharm Q1 EBITDA Up At SEK 250 Million

* Q1 NET SALES SEK 1.51 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

BRIEF-Recipharm Signs Licensing Agreement with Altus Formulation

* RECIPHARM AND ALTUS FORMULATION COLLABORATE TO OFFER NOVEL DRUG DELIVERY TECHNOLOGIES FOR VALUE ADDED MEDICINES

BRIEF-Recipharm CFO Resigns

* HENRIK STENQVIST WILL SERVE AS CFO UNTIL LATER IN SPRING.

BRIEF-Recipharm Q4 EBITDA At SEK 226 Million

* Q4 NET SALES SEK 1.40 BILLION VERSUS SEK 1.33 BILLION YEAR AGO

BRIEF-Recipharm Buys Remaining Shares In Nitin Lifesciences

* RECIPHARM ACQUIRES REMAINING SHARES IN NITIN LIFESCIENCES LTD

BRIEF-Recipharm commences new supply contract

* RECIPHARM COMMENCES NEW SUPPLY CONTRACT AND COMPLETES PURCHASE OF FACILITY IN SPAIN Source text for Eikon: Further company coverage: (Reporting By Anna Ringstrom)

BRIEF-Recipharm equips a further three facilities for U.S serialisation

* RECIPHARM EQUIPS A FURTHER THREE FACILITIES FOR US SERIALISATION Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 EBITDA SEK 103 MILLION VERSUS SEK 144 MILLION YEAR AGO

BRIEF-Recipharm to end operations in two facilities in Sweden

* TO START A PROCESS WITH INTENTION OF DISCONTINUING ACTIVITIES BOTH IN STOCKHOLM AND HÖGANÄS.

BRIEF-Recipharm Q3 EBITDA down at SEK ‍103​ mln

* Q3 NET SALES SEK 1.20 BILLION VERSUS SEK 1.14 BILLION YEAR AGO

BRIEF-Recipharm starts cooperation with Roche

* RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN

BRIEF-Recipharm, Kancera cooperate to manufacture clinical trial supply

* RECIPHARM AND KANCERA COLLABORATE TO MANUFACTURE CLINICAL TRIAL SUPPLY

BRIEF-Recipharm Q2 EBITDA SEK 242 million

* Q2 NET SALES SEK 1.40 BILLION VERSUS SEK 1.24 BILLION YEAR AGO

BRIEF-Recipharm and Lidds establish industrial manufacturing capabilities

* RECIPHARM AND LIDDS ESTABLISH INDUSTRIAL MANUFACTURING CAPABILITIES FOR A NOVEL PROSTATE CANCER PRODUCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Recipharm EBITDA margin falls to 12 pct in Q1

* Q1 net sales amounted to SEK 1,328 million (973), an increase of 37 pct

BRIEF-Recipharm appoints Henrik Stenqvist as new CFO

* Recipharm appoints Henrik Stenqvist as new Chief Financial Officer Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

BRIEF-Recipharm Q4 EBITDA 229 mln SEK

* Q4 net sales amounted to sek 1 333 million (863), an increase of 54%

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up